Table 5.
Outcomes | PBO | AM | ANT | Anti-IL12/23 | Anti-IL17 | Anti-TNF-α |
---|---|---|---|---|---|---|
PASI 50 | 0.171 | 0.421 | 0.520 | 0.997 | 0.571 | 0.819 |
PASI 75 | 0.167 | 0.341 | 0.493 | 0.854 | 0.980 | 0.666 |
PASI 90 | 0.168 | 0.356 | 0.518 | 0.829 | 0.995 | 0.632 |
DLQI | 0.342 | 0.495 | 0.506 | 0.842 | 0.617 | 0.699 |
PGA | 0.171 | 0.465 | 0.368 | 0.823 | 0.998 | 0.676 |
AAE | 0.782 | 0.474 | 0.904 | 0.580 | 0.281 | 0.480 |
Infection | 0.910 | 0.761 | 0.643 | 0.427 | 0.352 | 0.407 |
Nasopharyngitis | 0.874 | 0.643 | 0.588 | 0.454 | 0.517 | 0.423 |
Headache | 0.972 | 0.501 | 0.495 | 0.554 | 0.363 | 0.615 |
URTI | 0.861 | 0.171 | 0.745 | 0.602 | 0.415 | 0.706 |
Withdrawal | 0.359 | 0.179 | 0.702 | 0.800 | 0.669 | 0.791 |
PASI 50: ≥50% reduction in psoriasis area and severity index; PASI 75: ≥75% reduction in psoriasis area and severity index; PASI 90: ≥90% reduction in psoriasis area and severity index; DLQI: Dermatology Life Quality Index; PGA: Physician’s Global Assessment – minimal or cleared; AAE: all adverse events; URTI: upper respiratory tract infection; AM: anti-metabolites; anti-TNF-α: anti-tumor necrosis factor-α agents; ANT: anti-T-cell agents; anti-IL12/23: anti-interleukin-12/23 agents; anti-IL17: anti-interleukin-17 agents; PBO: placebo.